COPENHAGEN – Novo Nordisk shares edged lower on Friday, July 3, 2026, as investors assessed the implications of Medicare's first obesity coverage pathway for weight-loss drugs. The Danish pharmaceutical giant's stock traded at DKK 327.50 by 10:43 CEST, down 1.36%, underperforming the OMX Copenhagen 25 index, which slipped 0.26%.
Medicare Bridge Program Details
The Centers for Medicare & Medicaid Services (CMS) launched the GLP-1 Bridge program on July 1, 2026, offering eligible patients a monthly copay of $50 while drugmakers receive a net price of $245 per month. The program, which runs through December 31, 2027, operates outside the standard Part D payment framework. CMS estimates the program could generate approximately $11.2 billion in annualized value based on 3.8 million full-year users, though this figure excludes competitive products, adherence drop-off, and prior authorization requirements.
Market Reaction
The lower share price does not indicate a lack of demand but rather signals that new demand is being priced at a lower U.S. rate. At a USD/DKK exchange rate of 6.5264, Novo Nordisk's market capitalization stands at DKK 1.10 trillion. If 1 million patients use the program for a full year, annualized net sales would reach $2.94 billion (DKK 19.2 billion), representing about 1.7% of Novo's market value. With 3.8 million full-year users, the figure jumps to $11.17 billion (DKK 72.9 billion), or 6.6% of market cap. However, these figures represent the entire covered drug pool, not Novo's share alone.
Reuters reported that Novo's Wegovy injection and oral pill are covered under the Bridge program, alongside Eli Lilly's Zepbound KwikPen and Foundayo. Prior authorization remains a requirement for coverage.
Pricing Pressure
Novo's U.S. challenge increasingly centers on price rather than demand. In May, the company reported that adjusted U.S. sales declined 11% in the first quarter at constant exchange rates, primarily due to lower realized prices, partially offset by higher GLP-1 volumes. Adjusted obesity-care sales still grew 22% during the period.
Karen Andersen, head of healthcare equity research at Morningstar, told Barron's that the market had already incorporated the lower pricing and that she was not modeling a significant revenue boost from the Bridge program.
Prescription Growth
Despite pricing headwinds, demand for Wegovy remains robust. Novo Nordisk announced on July 1 that Wegovy pill prescriptions surpassed 3 million since its January launch. In May, the company reported crossing the 2 million mark, with more than 200,000 weekly prescriptions in the week ending April 17.
Jamey Millar, head of U.S. commercial operations at Novo, defended the program, describing it as a new, affordable pathway to an FDA-approved treatment for eligible Medicare patients.
Outlook and Guidance
CEO Mike Doustdar characterized Wegovy as driving a strong start to 2026 during the company's May earnings call. Novo Nordisk raised its adjusted 2026 sales and operating-profit outlook, now projecting a decline of 4% to 12% at constant exchange rates. The company is scheduled to release first-half results on August 5 at 0730 CEST.
